<DOC>
	<DOCNO>NCT01608737</DOCNO>
	<brief_summary>The objective study : 1 . To evaluate efficacy safety two different treatment regimen BI 201335 ( high dose give 12 week low dose give 24 week combination Pegylated interferon-a Ribavirin ( PegIFN/RBV ) compare PegIFN/RBV alone treatment-naïve ( TN ) chronic genotype 1 hepatitis C virus infect patient . 2 . Evaluate efficacy safety BI 201335 high dose give 12 week combination PegIFN/RBV give 24 48 week compare PegIFN/RBV alone chronic GT-1 hepatitis C virus infect relapser patient fail prior PegIFN/RBV treatment .</brief_summary>
	<brief_title>A Phase III Study BI201335 Treatment-naive Prior Relapser Patients With Chronic Hepatitis C Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Inclusion criterion : 1 . Chronic hepatitis C infection , diagnose positive antiHCV antibody detectable hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) screen addition : 1 . Positive antiHCV antibody detectable HCV RNA least 6 month prior screen , 2 . Liver biopsy consistent chronic HCV infection 2 . HCV genotype 1 infection confirm genotypic test screen 3 . Therapynaïve interferon , pegylated interferon , ribavirin ( cohort 1 ) . Or Confirmed prior relapse approve dose PegIFN/RBV ( Cohort 2 ) define undetectable HCV RNA ( base assay consider sensitive time treatment ) end treatment pegylated interferonbased regimen , HCV RNA detectable within 24 week treatment follow 4 . HCV RNA =1,000 IU/mL screen 5 . Documentation liver biopsy within 3 year fibroscan within 6 month prior randomisation 6 . Age 18 70 year 7 . Female patient : 1. document hysterectomy , 2. ovary remove , 3. document tubal ligation , 4. postmenopausal last menstrual period least 12 month prior screen , 5. childbearing potential negative serum pregnancy test screen Day 1 , , sexually active , agree use one appropriate medically accept method birth control date screen 7 month last dose ribavirin addition consistent correct use condom . Patients must agree breastfeed time date screen 7 month last dose ribavirin 6 . Medically accept method contraception females trial ethinyl estradiolcontaining contraceptive , diaphragm spermicide substance , intra uterine device . Male patient : 1. document sterile , 2. without pregnant female partner ( ) consistently correctly use condom female partner ( ) ( childbearing potential ) use one appropriate medically accept method birth control date screen 7 month last dose ribavirin . It responsibility male patient ensure partner ( ) pregnant prior screening study become pregnant treatment observation phase . Female partner childbearing potential perform monthly pregnancy test date screen 7 month last dose ribavirin ( test provide sponsor ) 8 . Signed informed consent form prior trial participation Exclusion criterion : 1 . HCV infection mixed genotype ( 1/2 , 1/3 , 1/4 ) diagnose genotypic test screen 2 . Evidence acute chronic liver disease due cause chronic HCV infection . Incidental steatosis diagnose biopsy exclusion criterion 3 . HIV coinfection 4 . Hepatitis B virus ( HBV ) infection base presence hepatitis B surface Antigen ( HBsAg ) 5 . Active malignancy , history malignancy within last 5 year prior screen ( exception appropriately treat basal cell carcinoma skin situ carcinoma uterine cervix ) 6 . Active , history alcohol illicit drug abuse cannabis within past 12 month 7 . A condition define one opinion investigator may put patient risk participation study , may influence result study , limit patient 's ability participate study 8 . Usage investigational drug within 30 day prior screen , plan usage investigational drug course study 9 . Received concomitant systemic antiviral , hematopoietic growth factor , immunomodulatory treatment within 30 day prior randomisation.Patients treat oral antiviral acyclovir , famciclovir valacyclovir recurrent herpes simplex infection ; oseltamivir zanamivir influenza A infection , may screen 10 . Received silymarin ( milk thistle ) , glycyrrhizin , Shosaikoto ( SST ) within 28 day prior randomisation throughout treatment phase 11 . Patients previously treat least one dose antiviral immunomodulatory drug interferon alfa ribavirin acute chronic HCV infection include restricted protease polymerase inhibitor 12 . Known hypersensitivity ingredient study drug 13 . Alpha fetoprotein value &gt; 100 ng/mL screening ; &gt; 20 ng/mL =100 ng/mL , patient may include evidence liver cancer appropriate imaging study ( e.g. , ultrasound , compute tomography ( CT ) scan , magnetic resonance imaging ( MRI ) ) within last 6 month prior randomisation ( Visit 2 ) Other exclusion criterion relate pegylated interferona and/or ribavirin restriction list .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>